Anatara Lifesciences Ltd (ANR) - Cash Flow Conversion Efficiency

Latest as of June 2025: -2.561x

Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has a cash flow conversion efficiency ratio of -2.561x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.37 Million ≈ $-971.13K USD) by net assets (AU$535.97K ≈ $379.23K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Anatara Lifesciences Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Anatara Lifesciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Anatara Lifesciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Anatara Lifesciences Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Anatara Lifesciences Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Reliance Global Group, Inc.
NASDAQ:EZRA
-0.077x
Leapfrog Acquisition Corporation Warrants
NASDAQ:LFACW
-0.014x
Nortec Minerals Corp
V:NVT
0.397x
Lambo Group Bhd
KLSE:0018
-0.022x
Asdion Bhd
KLSE:0068
0.009x
Metronic Global Bhd
KLSE:0043
-0.030x
Reinhold Europe AB
WAR:RHD
0.023x
Grupo Vasconia S.A.B
MX:VASCONI
0.006x

Annual Cash Flow Conversion Efficiency for Anatara Lifesciences Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Anatara Lifesciences Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ANR market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$535.97K
≈ $379.23K
AU$-2.27 Million
≈ $-1.61 Million
-4.239x -363.73%
2024-06-30 AU$1.36 Million
≈ $965.52K
AU$-1.25 Million
≈ $-882.61K
-0.914x +62.57%
2023-06-30 AU$924.54K
≈ $654.17K
AU$-2.26 Million
≈ $-1.60 Million
-2.442x -49.22%
2022-06-30 AU$1.36 Million
≈ $965.33K
AU$-2.23 Million
≈ $-1.58 Million
-1.637x -198.86%
2021-06-30 AU$3.83 Million
≈ $2.71 Million
AU$-2.10 Million
≈ $-1.48 Million
-0.548x +42.59%
2020-06-30 AU$2.86 Million
≈ $2.02 Million
AU$-2.72 Million
≈ $-1.93 Million
-0.954x -152.17%
2019-06-30 AU$5.92 Million
≈ $4.19 Million
AU$-2.24 Million
≈ $-1.58 Million
-0.378x +2.02%
2018-06-30 AU$8.59 Million
≈ $6.08 Million
AU$-3.32 Million
≈ $-2.35 Million
-0.386x -61.22%
2017-06-30 AU$12.02 Million
≈ $8.51 Million
AU$-2.88 Million
≈ $-2.04 Million
-0.239x -1050.92%
2016-06-30 AU$13.48 Million
≈ $9.53 Million
AU$-280.37K
≈ $-198.38K
-0.021x +94.08%
2015-06-30 AU$5.48 Million
≈ $3.88 Million
AU$-1.92 Million
≈ $-1.36 Million
-0.351x -296.93%
2014-06-30 AU$7.23 Million
≈ $5.11 Million
AU$-639.27K
≈ $-452.32K
-0.088x -114.01%
2013-06-30 AU$-280.65K
≈ $-198.58K
AU$-177.22K
≈ $-125.39K
0.631x --

About Anatara Lifesciences Ltd

AU:ANR Australia Biotechnology
Market Cap
$1.92 Million
AU$2.72 Million AUD
Market Cap Rank
#29994 Global
#1763 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$1.64
About

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more